CBL-514 for Subcutaneous Fat
What You Need to Know Before You Apply
What is the purpose of this trial?
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Who Is on the Research Team?
Anne Sheu
Principal Investigator
Caliway Biopharmaceuticals Co., Ltd.
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive up to 4 treatments of CBL-514 or placebo administered subcutaneously to the abdomen, once every 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CBL-514 Injection
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive CBL-514 administered up to 120 mL per treatment at a 4-weeks interval for up to 4 treatments.
Participants will receive 0.9% Sodium Chloride administered up to 120 mL per treatment at a 4-week interval for up to 4 treatments.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Caliway Biopharmaceuticals Co., Ltd.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.